Vemurafenib for high risk melanoma patients

04:55 EDT 11 Sep 2017 | ecancermedicalscience

Dr Lewis presents in a press conference at the ESMO 2017 Congress in Madrid data from a randomised, double-blind, placebo-controlled study of adjuvant vemurafenib in patients with completely resected, BRAFV600 melanoma at high risk for recurrence. Dr...

Original Article: Vemurafenib for high risk melanoma patients


More From BioPortfolio on "Vemurafenib for high risk melanoma patients"

Quick Search

Relevant Topic

Skin cancers
There are three main types of skin cancer: basal cell carcinoma, squamous cell carcinoma and malignant melanoma. Basal cell carcinoma Basal cell carcinoma, or BCC, is a cancer of the basal cells at the bottom of the epidermis. It’s very common ...